Facility Volume as a Prognosticator of Survival in Locally Advanced Papillary Thyroid Cancer

被引:2
|
作者
Abiri, Arash [1 ]
Pang, Jonathan C. [1 ]
Roman, Kelsey [1 ]
Goshtasbi, Khodayar [1 ]
Birkenbeuel, Jack L. [1 ]
Kuan, Edward C. [1 ]
Tjoa, Tjoson [1 ]
Haidar, Yarah M. [1 ]
机构
[1] Univ Calif Irvine, Dept Otolaryngol Head & Neck Surg, Orange, CA 92868 USA
来源
LARYNGOSCOPE | 2023年 / 133卷 / 02期
基金
美国国家卫生研究院;
关键词
papillary thyroid cancer; hospital volume; prognosis; survival; quality improvement; HOSPITAL VOLUME; RADIOACTIVE IODINE; PROVIDER VOLUME; SURGEON VOLUME; OUTCOMES; HEAD; CARE; MANAGEMENT; MORTALITY; TRENDS;
D O I
10.1002/lary.30280
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives To evaluate the influence of facility case-volume on survival in patients with locally advanced papillary thyroid cancer (PTC), and to identify prognostic case-volume thresholds for facilities managing this patient population. Study Design Retrospective database study. Methods The 2004-2017 National Cancer Database was queried for patients receiving definitive surgery for locally advanced PTC. Using K-means clustering and multivariable Cox proportional-hazards (CPH) regression, two groups with distinct spectrums of facility case-volumes were generated. Multivariable CPH regression and Kaplan-Meier analysis assessed for the influence of facility case-volume and the prognostic value of its stratification on overall survival (OS). Results Of 48,899 patients treated at 1304 facilities, there were 34,312 (70.2%) females and the mean age was 48.0 +/- 16.0 years. Increased facility volume was significantly associated with reduced all-cause mortality (HR 0.996; 95% CI, 0.992-0.999; p = 0.008). Five facility clusters were generated, from which two distinct cohorts were identified: low (LVF; <27 cases/year) and high (HVF; >= 27 cases/year) facility case-volume. Patients at HVFs were associated with reduced mortality compared to those at LVFs (HR 0.791; 95% CI, 0.678-0.923, p = 0.003). Kaplan-Meier analysis of propensity score-matched N0 and N1 patients demonstrated higher OS in HVF cohorts (all p < 0.001). Conclusions Facility case-volume was an independent predictor of improved OS in locally advanced PTC, indicating a possible survival benefit at high-volume medical centers. Specifically, independent of a number of sociodemographic and clinical factors, facilities that treated >= 27 cases per year were associated with increased OS. Patients with locally advanced PTC may, therefore, benefit from referrals to higher-volume facilities. Level of Evidence 4 Laryngoscope, 2022
引用
收藏
页码:443 / 450
页数:8
相关论文
共 50 条
  • [31] Role of Matrix Metalloproteinases and Their Inhibitors in Locally Invasive Papillary Thyroid Cancer
    Ivkovic, Irena
    Limani, Zgjim
    Jakovcevic, Antonia
    Huic, Drazen
    Prgomet, Drago
    BIOMEDICINES, 2022, 10 (12)
  • [32] Impact of Facility Surgical Volume on Survival in Patients With Cancer
    Stoltzfus, Kelsey C.
    Shen, Biyi
    Tchelebi, Leila
    Trifiletti, Daniel M.
    Gusani, Niraj J.
    Walter, Vonn
    Wang, Ming
    Zaorsky, Nicholas G.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (05): : 495 - +
  • [33] Preoperative recombinant adeno-viral human p53 gene (rAd-p53) therapy in treatment of locally advanced locally advanced papillary thyroid cancer (PTC) and folliculary thyroid cancer (FTC).
    Zhu, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] Radiation Therapy Demonstrates Persistent Overall Survival Benefit in Locally Advanced or Metastatic Anaplastic Thyroid Cancer
    Ma, J.
    Bell, A.
    Lok, B. H.
    Leeman, J. E.
    Anderson, E. S.
    Spielsinger, D.
    Brinkman, T.
    Sabol, C.
    Waldenberg, T.
    Temares, D.
    Riaz, N.
    McBride, S. M.
    Ganly, I.
    Shaha, A.
    Sherman, E.
    Lee, N.
    Tsai, C. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E285 - E286
  • [35] Effectiveness of preoperative radioactive iodine (131I) therapy for locally advanced papillary thyroid cancer:: A case report
    Shingu, K
    Kobayashi, S
    Yokoyama, S
    Shimizu, T
    Kasuga, Y
    Fujimori, M
    Ito, KI
    Hama, Y
    Amano, J
    THYROID, 1998, 8 (12) : 1113 - 1116
  • [36] Pharmacodynamic study of neoadjuvant vemurafenib (VEM) in patients (pts) with BRAF mutated, locally advanced papillary thyroid cancer (PTC).
    Cabanillas, Maria E.
    Holsinger, F. Christopher
    Sturgis, Erich M.
    Habra, Mouhammed Amir
    Davies, Michael A.
    Munsell, Mark F.
    French, Jena
    Busaidy, Naifa
    Hu, Mimi I-Nan
    Sherman, Steven I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] Neoadjuvant use of lenvatinib in locally advanced papillary thyroid carcinoma involving critical vessels
    Katoh, Hiroshi
    Kajita, Sabine
    Yokota, Mitsuo
    Sengoku, Norihiko
    Sangai, Takafumi
    INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY, 2020, 7 (03)
  • [38] Autophagy: A new target for advanced papillary thyroid cancer therapy
    Lin, Chi-Iou
    Whang, Edward E.
    Abramson, Michael A.
    Jiang, Xiaofeng
    Price, Brendan D.
    Donner, David B.
    Moore, Francis D., Jr.
    Ruan, Daniel T.
    SURGERY, 2009, 146 (06) : 1208 - 1214
  • [39] Survival Outcomes and Disparities in Surgery Refusal for Papillary Thyroid Cancer
    Bowers, Jade c.
    Savaliya, Bansi p.
    Raikot, Swathi r.
    Ahmed, Syeda hoorulain
    Shekouhi, Ramin
    Popp, Reed
    Popp, Kyle
    Sukniam, Kulkaew b.
    Kowkabany, Gabrielle
    Jimenez, Paola berrios
    Mubarak, Fatima
    Ekpeh, Esinam p.
    Bansal, Shivam
    Sharan, Seema
    Manaise, Harsheen k.
    Gabriel, Emmanuel m.
    ANTICANCER RESEARCH, 2024, 44 (12) : 5455 - 5461
  • [40] Impact of Lymph Node Ratio on Survival in Papillary Thyroid Cancer
    Schneider, David F.
    Chen, Herbert
    Sippel, Rebecca S.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (06) : 1906 - 1911